Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial
The Journal of Clinical Endocrinology & Metabolism · 22.04.2026 · 111 (5) · 1408-1417
DOI: 10.1210/clinem/dgaf589 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.11.2025. Verfasst von Trupti N Prasad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. Hauptthemen laut MEDLINE: Zoledronic Acid, Denosumab, Teriparatide, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Indian Society for Bone and Mineral Research (ISBMR), Endocrine Society of India (ESI).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Type 2 diabetes (T2D) increases fragility fracture risk despite normal/elevated areal bone mineral density (aBMD), attributed to compromised bone microarchitecture. However, evidence guiding pharmacologic management of diabetic bone disease remains limited.
Objective
We aimed to evaluate interim effects of zoledronate, denosumab, or teriparatide on bone microarchitecture in postmenopausal women with T2D at high fracture risk.
Methods
A 72-week, randomized, open-label, blinded-end point (PROBE) pilot clinical trial (CTRI/2022/02/039978) was conducted at a single tertiary care center in India. Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < −2.5 [corrected for T2D] with elevated FRAX®). Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks. The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius. Bone turnover markers (BTMs) were also evaluated.
Results
Baseline demographic, biochemical, aBMD, and HR-pQCT parameters were comparable across groups. Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius). Denosumab improved tibial trabecular vBMD and Tb.N. Zoledronate improved only tibial total vBMD. Microfinite element analysis–derived strength parameters were unchanged, except for a modest increase in tibial stiffness with denosumab. BTMs decreased with antiresorptives, increased with teriparatide, and showed an anabolic window by 6 weeks.
Conclusion
Teriparatide demonstrated early improvements in bone microarchitecture in postmenopausal women with T2D while denosumab showed a modest increase in bone stiffness at the distal tibia. Larger, adequately powered studies are needed to clarify the relative effects of anabolic and antiresorptive therapies in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
- Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
- Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
ORCID-Profile: Rimesh Pal
Förderung
- Indian Society for Bone and Mineral Research (ISBMR)
- Endocrine Society of India (ESI)
Zitieren
APA
Prasad, T. N., Pal, R., Bhadada, S. K., Ram, S., Singla, V., & Pulami, S. (2026). Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial. The Journal of Clinical Endocrinology & Metabolism, 111(5), 1408-1417. https://doi.org/10.1210/clinem/dgaf589
Vancouver
Prasad TN, Pal R, Bhadada SK, Ram S, Singla V, Pulami S. Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial. The Journal of Clinical Endocrinology & Metabolism. 2026;111(5):1408-1417. doi:10.1210/clinem/dgaf589
BibTeX
@article{Prasad2026,
author = {Prasad, Trupti N and Pal, Rimesh and Bhadada, Sanjay K and Ram, Sant and Singla, Veenu and Pulami, Seema},
title = {Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {5},
pages = {1408--1417},
doi = {10.1210/clinem/dgaf589}
}
EUVIMED